Helmsley Charitable Trust Awards $52 Million to Support the Global Platform for the Prevention of Autoimmune Diabetes
Release Date: 
11/06/2017
... (GPPAD; “gee-pad”) and its first trial – the Primary  Oral Insulin Trial (POInT). Leading GPPAD will be ... genetic risk of developing T1D autoimmunity and conducting primary  prevention clinical trials...





